Apostrophe has been acquired by Hims & Hers Health, Inc.
The private shareholders of Apostrophe have sold the company to Hims & Hers Health, Inc.
Founded in 2012 and based in Oakland, California, Apostrophe is a direct-to-patient teledermatology platform that provides individuals with access to tailored, clinical-quality treatment plans that are prescribed by board-certified dermatologists. Through its vertically integrated in-house pharmacy, the company creates premium Apostrophe-branded products that use bespoke combinations of topical formulas and oral medications to meet the unique needs of patients. Driven by its innovative telehealth model, well-recognized skincare brand and visionary leadership team, the company has experienced rapid growth over the past several years.
Based in San Francisco, California, Hims & Hers is a leading multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers.
Oaklins’ team in Los Angeles acted as advisor to the private shareholders of Apostrophe in this transaction.
Talk to the deal team
Adam Abramowitz
Oaklins Intrepid
Hayden Rosenthal
Oaklins Intrepid
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more